Development of Recombinant Toxins to Treat Hematologic Malignancies

NIH Pandemic-Era Grants

Pandemic Era Grants

2022

Document text

Principal Investigator: ROBERT  KREITMAN
Organization: DIVISION OF BASIC SCIENCES - NCI
Fiscal Year: 2022
Award: $1,340,622
Funding agency: National Cancer Institute

Overview. We focus on targeted therapy for hematologic malignancies, particularly hairy      cell leukemia (HCL), and other new therapies for HCL. Moxetumomab pasudotox (Moxe) contains      truncated Pseudomonas exotoxin (PE) fused to an anti-CD22 Fv fragment. Previously called HA22      or CAT-8015, it is an affinity-matured form of a previous molecule BL22 for targeting      hematologic malignancies, particularly HCL. We test combinations of chemotherapy and rituximab      to help determine the optimal therapy of newly diagnosed and multiply relapsed HCL, and to      better understand the behavior of HCL in immunotoxin-treated patients. We also test small      molecules as targeted therapy for HCL and poor-prognosis variants like HCLv. In the lab, we      use clinical samples from patients to investigate treatment efficacy and toxicity, and to      better understand the biology and pathogenesis of HCL/HCLv. Development of anti-CD22      recombinant immunotoxins for CD22+ B-cell malignancies. We reported multicenter phase 1 and 3      results for Moxe. Of 49 patients enrolled on the phase I trial, 33 received the highest dose      level, 50 ug/Kg x3, and in this group the complete remission (CR) rate was 64% with overall      response rate (ORR) 88%. We published that most of the evaluable CRs (11 of 20) were without      minimal residual disease (MRD), using the highest sensitivity standard assay, bone marrow      aspirate (BMA) flow cytometry. For the first time in HCL, we reported that eradication of MRD      was associated with a significantly longer CR duration. A worldwide pivotal trial in 80      patients, including 26 at NIH, met its primary endpoint with a durable CR rate of 36%. The      most important toxicities, reported earlier with BL22, included reversible capillary leak      syndrome (CLS) and hemolytic uremic syndrome (HUS), the latter a combination of transient      thrombocytopenia and renal insufficiency resolving without treatment. On 9/13/18 the FDA      approved Moxe for patients with relapsed/refractory HCL, the first time in decades that a new      treatment was approved for HCL and the first FDA approval for a recombinant immunotoxin. To      improve efficacy in HCL, we began a trial at NIH testing Moxe with rituximab, the latter to      decrease immunogenicity and to help kill HCL cells and to hasten MRD-free CR. We presented the      first 9 patients at ASCO 2021, reporting an MRD-free CR rate of 78%. Development of      MAb-chemotherapy combinations for early and relapsed/refractory HCL. For the past 30-35 years,      cladribine alone, or less commonly pentostatin alone, was the standard 1st and 2nd line      treatment of HCL, but without cure in most patients. To determine the value of rituximab added      to cladribine, newly diagnosed or once-relapsed HCL patients were randomized to cladribine      with either immediate or 6-month delayed rituximab, and MRD at 6 months and other time      points measured. As published in 2020, for 68 purine-analog naive HCL patients randomized 1:1,      1st line concurrent cladribine-rituximab (CDAR) eradicates MRD in 97%, vs 32% of patients with      cladribine alone (CDA) (p0.0001). In this protocol, delayed rituximab was given when MRD      was detected in blood and eradicates MRD in 2/3 of patients with most MRD-free CRs persisting      at a median follow-up of 6.5 years. Patients could get up to 2 courses of 8 weekly doses of      Rituximab. Of 68 patients treated with either approach, only 1 progressed to the point of      needing next treatment, vs 28% of 90 historical patients treated with CDA alone and followed      until retreatment was needed for relapse (p0.0001). Thus, while CDAR is superior with      respect to long-term MRD-free CR, CDA alone with delayed rituximab is also established as a      new standard of care for treatment of newly diagnosed HCL. Once-relapsed HCL patients are      continuing to be randomized on the trial. In the poor prognosis HCL variant (HCLv), concurrent      rituximab + cladribine was highly effective, establishing CDAR as a new standard of care for      early HCLv. We recently published long-term data from the 20 patient-cohort of HCLv showing a      95% CR rate, and 80% MRD-free CR rate. Eradication of MRD improved progression free survival      (PFS) and overall survival (OS), and TP53 mutations in HCLv decreased PFS and OS. To study      pentostatin-rituximab and bendamustine-rituximab (BR) combinations in HCL prospectively, a      randomized trial showed both regimens as a highly effective combination, particularly in      eradicating MRD, albeit with chemotherapy toxicities. Targeted therapy for HCL. Although the      BRAF V600E mutation is thought to be present in 100% of classic HCL, we showed that up to 20%      lack V600E (wild-type, WT), particularly those with unmutated IGHV4-34 immunoglobulin      rearrangement, which characterizes a variant first described by our group in 2009. For the      first time in HCL, we began treating BRAF V600E+ HCL patients by inhibiting both BRAF with      Dabrafenib and its downstream pathway MEK with Trametinib. This trial is part of a      Novartis-sponsored multicenter registration trial in many different BRAF V600E+ histologies,      which completed accrual. As part of this trial, we treated several patients with anaplastic      thyroid cancer (ATC), a rapidly fatal disease also expressing BRAF V600E, leading to the      approval of Dabrafenib and Trametinib by the FDA for the treatment of ATC. To continue      development of BRAF/MEK inhibition for HCL, we initiated a trial of BRAF inhibitor Encorafenib      and MEK inhibitor Binimetinib in HCL. For HCLv, which is BRAF WT, and those more aggressive      HCL cases which are also BRAF WT, we have initiated a trial of Binimetinib alone. As part of      this trial, we are determining if response to Binimetinib depends on the presence of MEK      mutations, which we have reported in about half of BRAF WT HCL/HCLv. Finally, we treated 20 of      the 37 patients enrolled on the multicenter BTK inhibitor Ibrutinib study run by Ohio State      University, and the report published. While agents targeting BRAF, MEK and BTK generally do      not eliminate MRD, they can achieve regression of nodal disease and may be useful as a bridge      to Moxe or Moxe-R which can then eliminate MRD. Laboratory research with other therapies for      hematologic malignancies. To better target HCL/HCLv, new potential drugs are also being tested      in cytotoxicity assays, including BRAF, MEK, BTK, and BCL-2 inhibitors. Using clinical samples      from HCL/HCLv patients, we are sequencing immunoglobulin rearrangements (IgH) unique to each      HCL patient, to study HCL biology and to design patient-specific PCR assays for MRD. The      RQ-PCR test can detect 1 HCL cell in 1 million normal cells, and we are testing deep      sequencing (MiSeq) for determining MRD as well. We are performing whole exome sequencing and      RNA transcriptome analysis for HCLv and BRAF WT HCL samples to determine what causes disease      in these variant cells. We have found genes which are characteristic of patients with HCL      and/or HCLv, including Myf6 which as we published is the most common gene expressed in HCL      compared to HCLv, and is expressed in 100% of HCL patients. Our work with this and other genes      may shed light on pathogenesis of HCL/HCLv and possible new treatments for these disorders. We      began several projects related to the COVID-19 pandemic. The first project, started very early      in the COVID pandemic, was to study the humoral immune symptom via its immunoglobulin      repertoire in otherwise healthy people acutely infected with COVID. The 2nd project was to      study the humoral immune system in HCL patients infected with COVID with respect to time since      their most recent treatment, and with respect to their normal B-cell *TRUNCATED*

Terms: <2'-Deoxy-2-chloroadenosine><2'-Deoxycoformycin><2-CDA><2-Chloro-2'-deoxyadenosine><2-Chlorodeoxyadenosine><2-chloro-2'-deoxy-adenosine><2CDA><ASCO><Active Follow-up><Acute><Affinity><Affinotoxins><American Society of Clinical Oncology><Anti-CD22><Anti-CD22 Recombinant Immunotoxin BL22><Antioncogene Protein p53><Aspirate><Aspirate substance><Assay><B blood cells><B cell><B cell lymphoma 2><B cell malignancy><B cells><B lymphoid malignancy><B-Cell Antigen CD22><B-Cell CLL/Lymphoma 2 Gene><B-Cells><B-Lymphocytes><B-cell><B-cell lymphoma/leukemia-2><B-raf-1><B3 antigen><BCL2><BCL2 gene><BL22><BL22 Immunotoxin [RFB4(dsFv) - PE38><BL22 immunotoxin><BRAF><BRAF gene><Bcl-2><Behavior><Bioassay><Biologic Assays><Biological Assay><Biology><Blood><Blood Reticuloendothelial System><Bone Marrow><Bone Marrow Reticuloendothelial System><C2B8 Monoclonal Antibody><CD22><CD22 Immunotoxin><CD22 antigen><CD22 gene><COVID><COVID crisis><COVID epidemic><COVID infected patient><COVID pandemic><COVID patient><COVID positive patient><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infected patient><COVID-19 pandemic><COVID-19 patient><COVID-19 positive patient><COVID-19 public health crisis><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 patient><COVID19 positive patient><COVID19 public health crisis><Capillary Leak Syndrome><CdA><Cell Body><Cells><Cellular Tumor Antigen P53><Characteristics><Chemoresistance><Chrysemonas><Cladribina><Cladribine><Clinical><CoV disease><Combination Drug Therapy><Cytotoxin-Antibody Conjugates><Data><Deoxycoformycin><Detectable Residual Disease><Development><Disease><Disease remission><Disorder><Dose><Drugs><Enrollment><Evaluable><Evaluable Disease><Exotoxins><FDA approved><Flavimonas><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Gasser's Syndrome><Genes><Genetic Alteration><Genetic Change><Genetic defect><Hairy Cell Leukemia><Hairy Cell Leukemia Variant><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><Hemolytic-Uremic Syndrome><Histology><Immune><Immune Globulins><Immune system><Immunes><Immunoglobulins><Immunotoxins><Kidney Failure><Kidney Insufficiency><Laboratory Research><Leukemic Reticuloendotheliosis><Light><Lytotoxicity><MEK inhibition><MEKs><MabThera><Malignant Hematologic Neoplasm><Measures><Medication><Minimal Residual Disease><Molecular><Monoclonal Antibody-Toxin Conjugates><Mutation><NIH><National Institutes of Health><Newly Diagnosed><Nipent><Nodal><Non-Polyadenylated RNA><Normal Cell><Ohio><Oncoprotein p53><P53><Pathogenesis><Pathway interactions><Patients><Pentostatin><Pentostatine><Persons><Pharmaceutic Preparations><Pharmaceutical Preparations><Phase><Phosphoprotein P53><Phosphoprotein pp53><Photoradiation><Polychemotherapy><Prognosis><Progression-Free Survivals><Protein TP53><Protocol><Protocols documentation><Pseudomonas><Publishing><RAFB1><RFB4(dsFv)-PE38 Immunotoxin><RFB4(dsFv)-PE38 recombinant immunotoxin><RNA><RNA Gene Products><Randomization trial><Randomized><Recombinants><Refractory><Regimen><Relapse><Remission><Renal Failure><Renal Insufficiency><Reporting><Residual Neoplasm><Retreatment><Ribonucleic Acid><Rituxan><Running><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infected patient><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SIGLEC2><Sampling><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Sialic Acid-Binding Immunoglobulin-Like Lectin 2><Symptoms><Systemic Capillary Leak Syndrome><TM-MKR><TP53><TP53 gene><TRP53><Testing><Thrombocytopenia><Thrombopenia><Time><Toxic effect><Toxicities><Toxicity due to chemotherapy><Toxin><Toxin-Antibody Conjugates><Toxin-Antibody Hybrids><Treatment Efficacy><Treatment-related toxicity><Tumor Markers><Tumor Protein p53><Tumor Protein p53 Gene><United States National Institutes of Health><Universities><Vaccination><Variant><Variation><Work><active followup><allergic/immunologic body system><allergic/immunologic organ system><anaplastic thyroid cancer><anaplastic thyroid carcinoma><anti-CD22 immunotoxin><bcl-2 Genes><ced9 homolog><chemoresistant><chemotherapy resistance><chemotherapy resistant><chemotherapy toxicity><chlorodeoxyadenosine><clinical development><cohort><combination chemotherapy><combination pharmacotherapy><combined drug therapy><corona virus disease><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infected patient><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 public health crisis><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 patient><coronavirus patient><cytotoxicity><deep sequencing><design><designing><developmental><drug/agent><enroll><exome sequencing><exome-seq><flow cytophotometry><follow up><follow-up><followed up><followup><genetic profiling><genome mutation><global gene expression><global transcription profile><hairy T cell leukemia><hairy cell leukemia cell><immunogenicity><improved><inhibitor><intervention efficacy><new drug treatments><new drugs><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><next generation therapeutics><novel drug treatments><novel drugs><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><optimal therapies><optimal treatments><p53 Antigen><p53 Genes><p53 Tumor Suppressor><pathway><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><phase 1 trial><phase I trial><primary end point><primary endpoint><prospective><protein p53><purine analog><randomisation><randomization><randomized trial><randomly assigned><re-treatment><response><rituximab><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><small molecule><standard of care><targeted agent><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic efficacy><therapeutic toxicity><therapy efficacy><therapy toxicity><transcriptome><treatment toxicity><tumor biomarker><tumor specific biomarker><v-raf Murine Sarcoma Viral Oncogene Homolog B1>